Position in TAK
as of Jun 30, 2026
· filed Aug 10, 2026
Position Value
$906,272
+$397,824 QoQ
Shares Held
56,536
+105.9% QoQ
Ownership
0.002%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#105
of 378 holders
Holding Since
Jun 2023
7 quarters on record
Voting authority
Sole 69%
Shared 15%
None 16%
Common Shares in TAK Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026Savant Capital, LLC holds $13,041,183 across 15 Drug Manufacturers - Specialty & Generic names. TAK ranks #5 (6.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | HLN |
Haleon plc
|
391,297 | $3,650,801 | |
| 2 | UTHR |
UNITED THERAPEUTICS Corp
|
3,845 | $2,083,336 | |
| 3 | VTRS |
Viatris Inc
|
74,919 | $1,189,713 | |
| 4 | KNSA |
Kiniksa Pharmaceuticals International, plc
|
15,478 | $989,818 | |
| 5 | TAK |
Takeda Pharmaceutical Co Ltd
This page
|
56,536 | $906,272 | |
| 6 | NBIX |
Neurocrine Biosciences Inc
|
5,342 | $900,340 | |
| 7 | LNTH |
Lantheus Holdings, Inc.
|
7,965 | $883,637 | |
| 8 | ZTS |
Zoetis Inc.
|
9,906 | $711,845 |
All Filings in TAK
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $906,272 | 56,536 | Shares | Sole | 2026-08-10 | |
| 2026-03-31 | $508,448 | 27,454 | Shares | Sole | 2026-05-04 | |
| 2025-12-31 | $327,078 | 20,980 | Shares | Sole | 2026-02-10 | |
| 2025-09-30 | $325,110 | 22,207 | Shares | Sole | 2026-03-04 | |
| 2025-06-30 | $406,025 | 26,263 | Shares | Sole | 2026-03-04 | |
| 2023-09-30 | $165,637 | 10,707 | Shares | Sole | 2023-11-07 | |
| 2023-06-30 | $173,595 | 11,050 | Shares | Sole | 2023-08-04 | |
| No filing history on record for this holder in this stock. | ||||||